MedPath

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Phase 3
Terminated
Conditions
Psoriasis
Interventions
Registration Number
NCT03556202
Lead Sponsor
Eli Lilly and Company
Brief Summary

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
1936
Inclusion Criteria
  • Participant must have completed the last visit of an eligible study period of originating study.
  • Participant must be willing to follow the birth control measures during and after study treatment if woman of childbearing potential.
Exclusion Criteria
  • Participant must not have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disease or abnormal lab results, that the study investigator thinks makes it unsafe or inappropriate for the participant to participate in this study.
  • Participant must not have stopped taking mirikizumab during a previous study or if the study investigator thinks restarting mirikizumab would create an unacceptable risk to the participant.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
125 Milligram (mg) Mirikizumab Q8WMirikizumabParticipants received 125 mg mirikizumab administered subcutaneously (SC) every eight weeks (Q8W).
250 mg Mirikizumab Q8W Excluding SecukinumabMirikizumabParticipants received 250 mg mirikizumab administered SC Q8W excluding participants who received secukinumab of their originating study (AMAJ)
Secukinumab/250 mg Mirikizumab Q8WMirikizumabParticipants from previous originating study \[who received secukinumab (AMAJ)\] received 250 mg mirikizumab administered SC Q8W.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants With a Static Physician's Global Assessment Among Those Who Entered the Study With a sPGA of 0,1Week 104

The sPGA is the physician's determination of the participant's psoriasis (PsO) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 104 were considered non-responders for non-responder Imputation (NRI) analysis.

Percentage of Participants Who Maintained a ≥90% Improvements in Psoriasis Area and Severity Index (PASI) 90 Among Those Who Entered the Study With a PASI 90Week 104

PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)Week 104

PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).

Percentage of Participants With a Psoriasis Symptoms Scale (PSS) Symptom Score of 0 (Free of Itch, Pain, Stinging, and Burning) in Those With a PSS Symptoms Score ≥1 at BaselineWeek 104

PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. In addition, a symptoms score ranging from 0 (no symptoms) to 40 (worst imaginable symptoms), and a sign score of 0 (no signs) to 30 (worst imaginable signs) will be reported.

Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Total Score of (0,1) With at Least a 5-Point Improvement (Reduction) From Baseline in Participants With a Baseline DLQI Total Score ≥5Week 104

The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Totals range from 0 to 30 (less to more impairment). A DLQI total score of 0 to 1 is considered as having no effect on a patient's health-related quality of life (HRQoL), and a 5-point change from baseline is considered as the minimal clinically important difference (MCID) threshold.

Change in Palmoplantar Psoriasis Severity Index (PPASI) Total Score in Participants With Palmoplantar Involvement at BaselineBaseline, Week 104

The PPASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline.

Change in Psoriasis Scalp Severity Index (PSSI) Total Score in Participants With Scalp Involvement at BaselineBaseline, Week 104

The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity).

Change in Nail Psoriasis Severity Index (NAPSI) Total Score in Participants With Fingernail Involvement at BaselineBaseline, Week 104

The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix PsO by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed PsO 0 (none) to 4 (PsO in 4 quadrants of the fingernail) and fingernail matrix PsO 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix PsO in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis).

Trial Locations

Locations (228)

Modern Research Associates

🇺🇸

Dallas, Texas, United States

Univ of Connecticut

🇺🇸

Farmington, Connecticut, United States

Dermatologic Surgery Specialists, PC

🇺🇸

Macon, Georgia, United States

Lawrence J Green, M.D, LLC

🇺🇸

Rockville, Maryland, United States

Centrum Medyczne Evimed

🇵🇱

Warsaw, Mazowieckie, Poland

LASER CLINIC Specjalistyczne Gabinety Lekarskie

🇵🇱

Szczecin, Zachodniopomorskie, Poland

Dermed Centrum Medyczne Sp. z o.o.

🇵🇱

Lodz, Lodzkie, Poland

Lubelskie Centrum Diagnostyczne

🇵🇱

Swidnik, Lubelskie, Poland

Santa Cruz Behavioral PSC

🇵🇷

Bayamón, Puerto Rico

Ponce School of Medicine CAIMED Center

🇵🇷

Ponce, Puerto Rico

University Hospitals Cleveland Medical Center

🇺🇸

Cleveland, Ohio, United States

Texas Dermatology and Laser Specialists

🇺🇸

San Antonio, Texas, United States

Dermatologische Gemeinschaftspraxis Mahlow

🇩🇪

Mahlow, Brandenburg, Germany

Universitätsklinikum Tübingen

🇩🇪

Tübingen, Baden-Württemberg, Germany

National Taiwan University Hospital - Hsinchu branch

🇨🇳

Hsinchu, Taiwan

Teikyo University Hospital

🇯🇵

Itabashi-ku, Tokyo, Japan

Austin Institute for Clinical Research

🇺🇸

Pflugerville, Texas, United States

Woden Dermatology

🇦🇺

Phillip, Australian Capital Territory, Australia

Grupo Clinico CATEI Sociedad Civil

🇲🇽

Guadalajara, Jalisco, Mexico

Taipei Medical University Shuang Ho Hospital

🇨🇳

New Taipei City, Taiwan

Chung Shan Medical University Hospital

🇨🇳

Taichung City, Taiwan

Sheba Medical Center

🇮🇱

Ramat Gan, Israel

Chonnam National University Hospital

🇰🇷

Gwangju, Korea, Korea, Republic of

Tokyo Medical University Hachioji Medical Center

🇯🇵

Hachioji, Tokyo, Japan

NZOZ Specjalistyczna Przychodnia Dermatologiczna Specderm

🇵🇱

Bialystok, Podlaskie, Poland

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Florida Academic Centers Research and Education, LLC

🇺🇸

Coral Gables, Florida, United States

First OC Dermatology

🇺🇸

Fountain Valley, California, United States

San Luis Dermatology & Laser Clinic

🇺🇸

San Luis Obispo, California, United States

Clinical Trials SA Pty Ltd

🇦🇺

Adelaide, South Australia, Australia

Nemocnice AGEL Novy Jicin a.s.

🇨🇿

Novy Jicin, Moravskoslezsky Kraj, Czechia

Fakultni Nemocnice U svate Anny

🇨🇿

Brno, Jihomoravský Kraj, Czechia

Fakultni nemocnice Kralovske Vinohrady

🇨🇿

Praha 10, Hl. M. Praha, Czechia

Eastern Canada Cutaneous Research Assoicates Ltd

🇨🇦

Halifax, Nova Scotia, Canada

Parra Dermatología

🇦🇷

Mendoza, Argentina

Skin Health Institute Inc.

🇦🇺

Carlton, Victoria, Australia

Alberta DermaSurgery Centre

🇨🇦

Edmonton, Alberta, Canada

Lynderm Research Inc.

🇨🇦

Markham, Ontario, Canada

Fremantle Dermatology

🇦🇺

Perth, Western Australia, Australia

Dr. Chih-ho Hong Medical Inc.

🇨🇦

Surrey, British Columbia, Canada

Klinikum der Johann Wolfgang Goethe-Universität Frankfurt

🇩🇪

Frankfurt am Main, Hessen, Germany

CHU de Bordeaux Hop St ANDRE

🇫🇷

Bordeaux, Gironde, France

Kožní ambulance Kutná Hora, s.r.o.

🇨🇿

Kutna Hora, Středočeský Kraj, Czechia

ISA GmbH

🇩🇪

Berlin, Germany

Rosenpark Research GmbH

🇩🇪

Darmstadt, Hessen, Germany

Clinical Research Hamburg GmbH

🇩🇪

Hamburg, Germany

Dermatologisches Zentrum Osnabrück Nord

🇩🇪

Bramsche, Niedersachsen, Germany

Universitätsklinikum Schleswig-Holstein

🇩🇪

Lübeck, Schleswig-Holstein, Germany

Debreceni Egyetem Klinikai Kozpont Borgyogyaszati Klinika

🇭🇺

Debrecen, Hajdu-Bihar, Hungary

Universitaetsklinikum Hamburg-Eppendorf

🇩🇪

Hamburg, Germany

Uno Medical Trials Kft.

🇭🇺

Budapest, Hungary

Medmare Bt

🇭🇺

Veszprém, Veszprém City, Hungary

Allergo-Derm Bakos Kft

🇭🇺

Szolnok, Jasz-Nagykun-Szolnok, Hungary

Ambrozia Kft.

🇭🇺

Budapest, Hungary

Rambam Medical Center

🇮🇱

Haifa, Israel

Haemek Medical Center- Dermatology

🇮🇱

Afula, Israel

Policlinico Gemelli - Università Cattolica del Sacro Cuore

🇮🇹

Roma, Lazio, Italy

The University of Tokyo Hospital

🇯🇵

Bunkyo-ku, Tokyo, Japan

Policlinico di Tor Vergata

🇮🇹

Roma, Italy

Tokai University Hospital- Isehara Campus

🇯🇵

Isehara, Kanagawa, Japan

Presidio Ospedaliero Firenze Centro Piero Palagi

🇮🇹

Firenze, Italy

Rabin Medical Center

🇮🇱

Petach Tikva, Israel

Gunma University Hosptial

🇯🇵

Maebashi, Gunma, Japan

Showa University Hospital

🇯🇵

Shinagawa, Tokyo, Japan

Tokyo Medical University Hospital

🇯🇵

Shinjuku-ku, Tokyo, Japan

Ryukyu University Hospital

🇯🇵

Nakagami-gun, Okinawa, Japan

Shiga University of Medical Science Hosptial

🇯🇵

Ōtsu, Shiga, Japan

Yamanashi Prefectural Central Hospital

🇯🇵

Kofu, Yamanashi, Japan

Osaka City University Hospital

🇯🇵

Osaka, Japan

Bucheon St. Mary's Hospital

🇰🇷

Bucheon,, Gyeonggi-do, Korea, Republic of

CHA Bundang Medical Center, CHA University

🇰🇷

Sungnam-si, Gyeonggi-do, Korea, Republic of

Seoul National University Bundang Hospital

🇰🇷

Seongnam-si, Gyeonggi-do, Korea, Republic of

Nippon Life Hospital

🇯🇵

Osaka, Japan

Ajou University Hospital

🇰🇷

Suwon, Gyeonggi-do, Korea, Republic of

Ilsan Paik Hospital

🇰🇷

Goyang-si, Gyeonggi-do, Korea, Republic of

B&B Investigaciones Medicas, SC

🇲🇽

Mazatlan, Sinaloa, Mexico

Centro Medico del Angel

🇲🇽

Mexicali, Baja California, Mexico

Hospital de Jesus I.A.P.

🇲🇽

Mexico City, Distrito Federal, Mexico

Chungang University Hospital

🇰🇷

Seoul, Korea, Republic of

Centrum Medyczne AMED

🇵🇱

Warsaw, Mazowieckie, Poland

Ai Centrum Medyczne Sp. Z O.O. Sp.K.

🇵🇱

Poznan, Wielkopolskie, Poland

RM Pharma Specialists S.A. de C.V.

🇲🇽

Distrito Federal, Mexico

Clinica De Enfermedades Cronicas y Procedimientos Especiales

🇲🇽

Morelia, Michoacan, Mexico

Köhler & Milstein Research

🇲🇽

Mérida, Yucatan, Mexico

Instituto de Investigaciones Aplicadas a la Neurociencia A.C

🇲🇽

Durango, Mexico

dermMedica Sp. z o.o.

🇵🇱

Wrocław, Dolnośląskie, Poland

DermoDent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski s.c.

🇵🇱

Osielsko, Kujawsko-pomorskie, Poland

Diamond Clinic

🇵🇱

Krakow, Malopolskie, Poland

Centralny Szpital Kliniczny MSW Klinika Dermatologii

🇵🇱

Warszawa, Poland

Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna

🇵🇱

Lodz, Łódzkie, Poland

NZOZ ZDROWIE Osteo-Medic

🇵🇱

Bialystok, Podlaskie, Poland

Dr. Samuel Sanchez PSC

🇵🇷

Caguas, Puerto Rico

Hospital Germans Trias i Pujol

🇪🇸

Barcelona, Badalona, Spain

Hospital de Manises

🇪🇸

Manises, Valencia, Spain

State scientific centre for dermatovenerology and cosmetolog

🇷🇺

Moscow, Russian Federation

Hospital Universitario La Fe de Valencia

🇪🇸

Valencia, Spain

Hospital Marina Baixa

🇪🇸

Villajoyosa, Alicante, Spain

SPb SBHI Skin-venerologic dispensary #10

🇷🇺

St. Petersburg, Russian Federation

Centro de Especialidades Mollabao

🇪🇸

Pontevedra, Spain

Hospital De Basurto

🇪🇸

Bilbao, Vizcaya, Spain

National Cheng-Kung Uni. Hosp.

🇨🇳

Tainan, Taiwan

Chang Gung Memorial Hospital - Linkou

🇨🇳

Taoyuan Hsien, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei City, Taiwan

Salford Royal NHS Foundation Trust

🇬🇧

Salford, Greater Manchester, United Kingdom

Kirk Barber Research

🇨🇦

Calgary, Alberta, Canada

Innovaderm Research Inc

🇨🇦

Montreal, Quebec, Canada

Nagoya City University Hospital

🇯🇵

Nagoya, Aichi, Japan

Toho University School of Medicine, Sakura Hospital

🇯🇵

Sakura, Chiba, Japan

Juntendo Urayasu Hospital

🇯🇵

Urayasu, Chiba, Japan

Kurume University Hospital

🇯🇵

Kurume, Fukuoka, Japan

Asahikawa Medical College Hospital

🇯🇵

Asahikawa, Hokkaido, Japan

Takagi Dermatology

🇯🇵

Obihiro, Hokkaido, Japan

Tokyo Medical University Ibaraki Medical Center

🇯🇵

Inashiki, Ibaraki, Japan

Yokohama City University Hospital

🇯🇵

Yokohama, Kanagawa, Japan

Shinshu University Hospital

🇯🇵

Matsumoto, Nagano, Japan

Tohoku University Hospital

🇯🇵

Sendai-shi, Miyagi, Japan

Kansai Medical University Hospital

🇯🇵

Hirakata, Osaka, Japan

Gifu University Hospital

🇯🇵

Gifu, Japan

St. Luke's International Hospital

🇯🇵

Tokyo, Japan

Shimane University Hospital

🇯🇵

Izumo, Shimane, Japan

Takaokashi Shirasaki Dermatology Clinic

🇯🇵

Takaoka, Toyama, Japan

Yamaguchi University Hospital

🇯🇵

Ube, Yamaguchi, Japan

Kyoto Furitsu Medical University Hospital

🇯🇵

Kyoto, Japan

Wakayama Medical University Hospital

🇯🇵

Wakayama, Japan

Pusan National University Hospital

🇰🇷

Busan, Korea, Korea, Republic of

Gachon University Gil Hospital

🇰🇷

Incheon, Korea, Korea, Republic of

Hanyang University Medical Center

🇰🇷

Seoul, Korea, Korea, Republic of

Seoul St. Mary's Hospital

🇰🇷

Seoul, Korea, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of

Ulsan University Hospital

🇰🇷

Ulsan, Ulsan-Kwangyǒkshi, Korea, Republic of

Fachklinik Bad Bentheim

🇩🇪

Bad Bentheim, Niedersachsen, Germany

Klin. Forschung Berlin-Mitte GmbH

🇩🇪

Berlin, Germany

TFS Trial Form Support GmbH

🇩🇪

Hamburg, Germany

Hospital Infanta Leonor

🇪🇸

Madrid, Spain

Hospital Universitario Virgen Macarena

🇪🇸

Sevilla, Spain

Hospital Universitario Ramón y Cajal

🇪🇸

Madrid, Spain

GOU VPO 'Smolensk State Medical Academy of Ministry of Health and Social Development of Russian Federation'

🇷🇺

Smolensk, Russian Federation

Tver State Medical University

🇷🇺

Tver, Russian Federation

Dermatology Clinical Trials

🇺🇸

Newport Beach, California, United States

Zenith Research, Inc.

🇺🇸

Beverly Hills, California, United States

Keck School of Medicine University of Southern California

🇺🇸

Los Angeles, California, United States

Renstar Medical Research

🇺🇸

Ocala, Florida, United States

Clinical Science Institute

🇺🇸

Santa Monica, California, United States

ForCare Clinical Research

🇺🇸

Tampa, Florida, United States

Park Avenue Dermatology

🇺🇸

Orange Park, Florida, United States

Arlington Dermatology

🇺🇸

Rolling Meadows, Illinois, United States

The Indiana Clinical Trials Center

🇺🇸

Plainfield, Indiana, United States

Meridian Clinical Research

🇺🇸

Savannah, Georgia, United States

University Dermatology

🇺🇸

Darien, Illinois, United States

Forefront Research

🇺🇸

Louisville, Kentucky, United States

The South Bend Clinic Center for Research

🇺🇸

South Bend, Indiana, United States

DelRicht Research

🇺🇸

Baton Rouge, Louisiana, United States

Dermatology and Skin Cancer Specialists

🇺🇸

Rockville, Maryland, United States

ORA, Inc

🇺🇸

Andover, Massachusetts, United States

Central Dermatology PC

🇺🇸

Saint Louis, Missouri, United States

Psoriasis Treatment Center of Central New Jersey

🇺🇸

East Windsor, New Jersey, United States

Mount Sinai School of Medicine Dermatology Clinical Trials

🇺🇸

New York, New York, United States

Wright State Univ School of Medicine

🇺🇸

Fairborn, Ohio, United States

PMG Research of Cary, LLC

🇺🇸

Cary, North Carolina, United States

Oregon Health and Science University

🇺🇸

Portland, Oregon, United States

Bexley Dermatology Research

🇺🇸

Bexley, Ohio, United States

Oregon Dermatology and Research Center

🇺🇸

Portland, Oregon, United States

PMG Research of Wilmington

🇺🇸

Wilmington, North Carolina, United States

Oregon Medical Research Center

🇺🇸

Portland, Oregon, United States

The Pennsylvania Centre for Dermatology, LLC

🇺🇸

Exton, Pennsylvania, United States

Clinical Partners, LLC

🇺🇸

Johnston, Rhode Island, United States

Virginia Clinical Research, Inc.

🇺🇸

Norfolk, Virginia, United States

University of Utah

🇺🇸

Murray, Utah, United States

Dermatology Associates

🇺🇸

Seattle, Washington, United States

Dermatology

🇦🇷

Caba, Buenos Aires, Argentina

MultiCare Good Samaritan Hospital

🇺🇸

Tacoma, Washington, United States

Instituto de Neumonología Y Dermatología

🇦🇷

Capital Federal, Buenos Aires, Argentina

Psoriahue

🇦🇷

Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

Clinica Adventista Belgrano

🇦🇷

Caba, Ciudad Autónoma De Buenos Aire, Argentina

Centro de Investigaciones Metabólicas (CINME)

🇦🇷

Buenos Aires, Argentina

Buenos Aires Skin

🇦🇷

Buenos Aires, Ciudad Autónoma De Buenos Aire, Argentina

Clintrial s.r.o.

🇨🇿

Praha, Praha 10, Czechia

K. Papp Clinical Research

🇨🇦

Waterloo, Ontario, Canada

Etická komise Krajské zdravotní, a.s. - Masarykovy nemocnice v Ústí nad Labem, o.z.

🇨🇿

Usti nad Labem, Ustecký Kraj, Czechia

CHU Dupuytren 2

🇫🇷

Limoges, Cedex, France

Hopital Saint Eloi

🇫🇷

Montpellier, France

CHU de Nice Hopital de L'Archet

🇫🇷

Nice cedex 3, France

Cabinet Médical

🇫🇷

Martigues, France

CH du Mans - Pavillon Claude Monet

🇫🇷

Le Mans Cedex 1, France

CHU Charles Nicolle in Rouen

🇫🇷

Rouen cedex, France

Hopital Larrey

🇫🇷

Toulouse cedex 9, France

Hautarztpraxis Dr. Leitz

🇩🇪

Stuttgart, Baden-Württemberg, Germany

Oroshaza Varosi Onkormanyzat Korhaza

🇭🇺

Oroshaza, Bekes, Hungary

Bacs-Kiskun Megyei Korhaz

🇭🇺

Kecskemét, Bács-Kiskun, Hungary

Soroka Medical Center

🇮🇱

Beer Sheva, Israel

Tel Aviv Sourasky Medical Center

🇮🇱

Tel Aviv, Israel

Istituto Clinico Humanitas

🇮🇹

Rozzano, Milano, Italy

Mie University Hospital

🇯🇵

Tsu, Mie, Japan

Kanto Rosai Hospital

🇯🇵

Kawasaki, Kanagawa, Japan

Kume Clinic

🇯🇵

Nishi-ku Sakai-shi, Osaka, Japan

Nihon University Itabashi Hospital

🇯🇵

Itabashi-ku, Tokyo, Japan

Chungnam National University Hospital

🇰🇷

Daejeon, Korea, Korea, Republic of

Kyung Hee University Hospital

🇰🇷

Seoul, Korea, Korea, Republic of

Konkuk University Medical Center

🇰🇷

Seoul, Korea, Republic of

Severance Hospital, Yonsei University Health System

🇰🇷

Seoul, Korea, Republic of

Centrum Badan Klinicznych PI-House sp. z o.o.

🇵🇱

Gdansk, Pomorskie, Poland

Centrum Medyczne Angelius Provita

🇵🇱

Katowice, Śląskie, Poland

GBUZ Clinical dermatology and venereological dispensary

🇷🇺

Krasnodar, Krasnodarskiy Kray, Russian Federation

Hospital Reina Sofia

🇪🇸

Cordoba, Spain

Hospital del Mar

🇪🇸

Barcelona, Spain

Chang Gung Memorial Hospital - Kaohsiung Branch

🇨🇳

Kaohsiung, Taiwan

Elbe Klinikum Buxtehude

🇩🇪

Buxtehude, Niedersachsen, Germany

California Dermatology & Clinical Research Institute

🇺🇸

Encinitas, California, United States

Advanced Clinical Research LLC

🇺🇸

Meridian, Idaho, United States

Dawes Fretzin Clinical Research Group, LLC

🇺🇸

Indianapolis, Indiana, United States

University of North Carolina Dermatology and Skin Cancer Cen

🇺🇸

Chapel Hill, North Carolina, United States

Halitus Instituto Médico

🇦🇷

Ciudad Autonoma de Buenos Aire, Argentina

Hautarztpraxis Dr. Gerlach

🇩🇪

Dresden, Sachsen, Germany

Veracity Clinical Research Pty Ltd

🇦🇺

Woolloongabba, Queensland, Australia

SKiN Centre for Dermatology

🇨🇦

Peterborough, Ontario, Canada

Universitätsklinikum Münster

🇩🇪

Münster, Nordrhein-Westfalen, Germany

Charité Campus Virchow-Klinikum

🇩🇪

Berlin, Germany

Tokushima University Hospital

🇯🇵

Tokushima, Japan

Korea University Guro Hospital

🇰🇷

Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of

Nagasaki University Hospital

🇯🇵

Nagasaki, Japan

Hospital Universitario La Paz

🇪🇸

Madrid, Spain

Office of Dr. Alma M. Cruz

🇵🇷

Carolina, Puerto Rico

GCM Medical Group, PSC - Hato Rey Site

🇵🇷

San Juan, Puerto Rico

Rothhaar Studien

🇩🇪

Berlin, Germany

Guenther Research Inc.

🇨🇦

London, Ontario, Canada

Universitätsklinikum Heidelberg

🇩🇪

Heidelberg, Baden-Württemberg, Germany

Seibo Hospital

🇯🇵

Shinjuku-ku, Tokyo, Japan

NTT Medical Center Tokyo

🇯🇵

Shinagawa-KU, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath